4.7 Article

Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery

Journal

INTERNATIONAL JOURNAL OF NANOMEDICINE
Volume 13, Issue -, Pages 4015-4027

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S164393

Keywords

nanoparticles; lyophilization; cancer; mesoporous silica; antibody; siRNA

Funding

  1. NCI/SBIR [HHSN261201300078C, R44CA217534]
  2. NCATS/SBIR [R43TR001906]
  3. Prospect Creek Foundation
  4. OHSU's VPR fund

Ask authors/readers for more resources

Introduction: Long-term stability of therapeutic candidates is necessary toward their clinical applications. For most nanoparticle systems formulated in aqueous solutions, lyophilization or freeze-drying is a common method to ensure long-term stability. While lyophilization of lipid, polymeric, or inorganic nanoparticles have been studied, little has been reported on lyophilization and stability of hybrid nanoparticle systems, consisting of polymers, inorganic particles, and antibody. Lyophilization of complex nanoparticle systems can be challenging with respect to preserving physicochemical properties and the biological activities of the materials. We recently reported an effective small-interfering RNA (siRNA) nanoparticle carrier consisting of 50-nm mesoporous silica nanoparticles decorated with a copolymer of polyethylenimine and polyethyleneglycol, and antibody. Materials and methods: Toward future personalized medicine, the nanoparticle carriers were lyophilized alone and loaded with siRNA upon reconstitution by a few minutes of simple mixing in phosphate-buffered saline. Herein, we optimize the lyophilization of the nanoparticles in terms of buffers, lyoprotectants, reconstitution, and time and temperature of freezing and drying steps, and monitor the physical and chemical properties (reconstitution, hydrodynamic size, charge, and siRNA loading) and biological activities (gene silencing, cancer cell killing) of the materials after storing at various temperatures and times. Results: The material was best formulated in Tris-HCl buffer with 5% w/w trehalose. Freezing step was performed at -55 degrees C for 3 h, followed by a primary drying step at -40 degrees C (100 mu Bar) for 24 h and a secondary drying step at 20 degrees C (20 mu Bar) for 12 h. The lyophilized material can be stored stably for 2 months at 4 degrees C and at least 6 months at -20 degrees C. Conclusion: We successfully developed the lyophilization process that should be applicable to other similar nanoparticle systems consisting of inorganic nanoparticle cores modified with cationic polymers, PEG, and antibodies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Multidisciplinary

Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer

Worapol Ngamcherdtrakul, Jingga Morry, Shenda Gu, David J. Castro, Shaun M. Goodyear, Thanapon Sangvanich, Moataz M. Reda, Richard Lee, Samuel A. Mihelic, Brandon L. Beckman, Zhi Hu, Joe W. Gray, Wassana Yantasee

ADVANCED FUNCTIONAL MATERIALS (2015)

Article Engineering, Biomedical

Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis

Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Shaun M. Goodyear, David J. Castro, Moataz M. Reda, Thanapon Sangvanich, Wassana Yantasee

BIOMATERIALS (2015)

Review Oncology

Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment

Worapol Ngamcherdtrakul, David J. Castro, Shenda Gu, Jingga Morry, Moataz Reda, Joe W. Gray, Wassana Yantasee

CANCER TREATMENT REVIEWS (2016)

Article Oncology

Therapeutic siRNA for drug-resistant HER2-positive breast cancer

Shenda Gu, Zhi Hu, Worapol Ngamcherdtrakul, David J. Castro, Jingga Morry, Moataz M. Reda, Joe W. Gray, Wassana Yantasee

ONCOTARGET (2016)

Article Oncology

Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform

Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J. Castro, Thanapon Sangvanich, Joe W. Gray, Wassana Yantasee

MOLECULAR CANCER THERAPEUTICS (2017)

Article Multidisciplinary Sciences

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment

Shenda Gu, Worapol Ngamcherdtrakul, Moataz Reda, Zhi Hu, Joe W. Gray, Wassana Yantasee

PLOS ONE (2018)

Review Medicine, Research & Experimental

Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections

Mohamed Shehata Draz, Binbin Amanda Fang, Pengfei Zhang, Zhi Hu, Shenda Gu, Kevin C. Weng, Joe W. Gray, Fanqing Frank Chen

THERANOSTICS (2014)

Article Oncology

PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer

Moataz Reda, Worapol Ngamcherdtrakul, Shenda Gu, Daniel S. Bejan, Natnaree Siriwon, Joe W. Gray, Wassana Yantasee

CANCER LETTERS (2019)

Article Chemistry, Multidisciplinary

Structure-guided design and characterization of a clickable, covalent PARP16 inhibitor

Daniel S. Bejan, Sunil Sundalam, Haihong Jin, Rory K. Morgan, Ilsa T. Kirby, Ivan R. Siordia, Barr Tivon, Nir London, Michael S. Cohen

Summary: PARP16, a potential therapeutic target for cancer treatment, has poorly understood catalytic activity. This study describes the design of a selective PARP16 inhibitor and reveals that the catalytic activity of PARP16 regulates its solubility in response to nutrient stress.

CHEMICAL SCIENCE (2022)

Article Biochemistry & Molecular Biology

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Vinayak Palve, Claire E. Knezevic, Daniel S. Bejan, Yunting Luo, Xueli Li, Silvia Novakova, Eric A. Welsh, Bin Fang, Fumi Kinose, Eric B. Haura, Alvaro N. Monteiro, John M. Koomen, Michael S. Cohen, Harshani R. Lawrence, Uwe Rix

Summary: This study identifies the differential efficacy of multiple PARP inhibitors in small cell lung cancer cells. Talazoparib displays the highest potency and targets PARP16 in addition to PARP1. Silencing PARP16 significantly reduces cell survival, especially in combination with PARP1 inhibition.

CELL CHEMICAL BIOLOGY (2022)

Article Biotechnology & Applied Microbiology

Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis

Worapol Ngamcherdtrakul, Thanapon Sangvanich, Shaun Goodyear, Moataz Reda, Shenda Gu, David J. Castro, Primana Punnakitikashem, Wassana Yantasee

BIOENGINEERING-BASEL (2019)

Article Oncology

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer

Zhi Hu, Jian-Hua Mao, Christina Curtis, Ge Huang, Shenda Gu, Laura Heiser, Marc E. Lenburg, James E. Korkola, Nora Bayani, Shamith Samarajiwa, Jose A. Seoane, Mark A. Dane, Amanda Esch, Heidi S. Feiler, Nicholas J. Wang, Mary Ann Hardwicke, Sylvie Laquerre, Jeff Jackson, Kenneth W. Wood, Barbara Weber, Paul T. Spellman, Samuel Aparicio, Richard Wooster, Carlos Caldas, Joe W. Gray

BREAST CANCER RESEARCH (2016)

No Data Available